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The UK’s 100,000 Genomes Project has the aim of sequencing 100,000
genomes from UK National Health Service (NHS) patients while
concomitantly transforming clinical care such that whole genome sequencing
becomes routine clinical practice in the UK. Policymakers claim that the
project will revolutionize NHS care. We wished to explore the 100,000
Genomes Project, and in particular, the extent to which policymaker claims
have helped or hindered the work of those associated with Genomics
England – the company established by the Department of Health to deliver
the project. We interviewed 20 individuals linked to, or working for
Genomics England. Interviewees had double-edged views about the context
within which they were working. On the one hand, policymakers’
expectations attached to the venture were considered vacuous “genohype”;
on the other hand, they were considered the impetus needed for those trying
to advance genomic research into clinical practice. Findings should be
considered for future genomes projects.
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Introduction
The United Kingdom’s (UK) 100,000 Genomes Project aims to sequence 100,000
genomes from UKNational Health Service (NHS) patients who have a rare disease,
an infectious disease, or cancer by 2017. Launched in 2012, its central goal is to
implement genomics innovation/testing on a national scale such that it becomes
routine in NHS practice. Alongside this, it also has a research goal to provide
data for scientiﬁc discovery, making it the ﬁrst ever research–clinical hybrid
project within an NHS.1 The project has been described by policymakers as “revo-
lutionis[ing] [the] ﬁght against cancer and help[ing] 100,000 NHS patients”
(Gov.uk. 2012) with “the potential to transform the future of healthcare . . . ”
(NHS England 2014; our underline).
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Such hyped descriptions of genetic/genomic innovations are not new. Scholars
report a general “genetic optimism frame” within media and political represen-
tations of such technologies, which is now commonly referred to as “genohpye”
(Nelkin 1995; Petersen 2001; Nerlich, Dingwall, and Clarke 2002). Such hype
has been shown to over-emphasize the beneﬁts of genetics/genomics through
“breakthrough narratives,” and underrepresent the risks (Nerlich, Dingwall, and
Clarke 2002; Bubela and Caulﬁeld 2004; Henderson and Kitzinger 2007). Some
social scientists have argued that such reporting has led to broken promises and
hopes for the public and patients, and a public mistrust of genetic innovation and
science, more generally (Fitzgerald 1998; Zurr and Catts 2005). Other social scien-
tists – those exploring the sociology of expectations and those exploring related
notions of promissory discourses – have shown how this hype is not simply a
by-product of innovation, but rather constitutes the innovation process itself (van
Lente 1993; Michael 2000; Fortun 2001, 2005, 2008; Brown and Michael 2003;
Borup et al. 2006; Hilgartner 2015). By envisaging futures in the present using
breakthrough narratives and future expectations, it creates a shared positive
vision of the technology. This acts performatively by prompting alliance building
and securing funding. In essence, hype associated with biomedical technology acts
as a currency of “promissory capital” to drive the genetic bioeconomy and generate
funding opportunities (Fortun 2001, 2005, 2008; Thompson 2005; Petersen and
Krisjansen 2015; Joyner, Paneth, and Ioannidis 2016). The performative effects
of previous genohype could, in fact, be argued to have played a role in the
launch of the UK’s 100,000 Genomes Project.
The 100,000 Genomes Project has promised to transform the NHS by 2017. It
has sufﬁcient funding, and the Department of Health has speciﬁcally established
an organization – Genomics England – to ensure its goals are achieved. We
wanted to explore Genomics England, and in particular how policymakers’ expec-
tations associated with the project have helped or hindered those trying to deliver
the project into clinical practice – especially since clinical implementation projects
are not always easy to implement “on the ground” (Rogers 2003; May and Finch
2009; Peters et al. 2013; Williams 2014; Day et al. 2016; Manolio, Ward, and Gins-
burg 2016; The National Academies of Sciences 2016). We were not necessarily
interested in the clinical implementation process itself, or providing a deep descrip-
tion of what was happening in clinical practice, but rather how the company set up
to deliver the project, Genomics England, was functioning under the umbrella of
policymakers’ expectations.
Using an interview methodology, in 2016, we explored the views and experi-
ences of 20 individuals associated with, or working for Genomics England. We dis-
covered interesting views within the group regarding the extent to which they felt
helped or hindered by the “genohyped” context within which they were operating
and we discuss these. We believe these ﬁndings will be useful considerations for
any future genomes projects within the UK or internationally. Before doing so
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we provide a detailed overview of the 100,000 Genomes Project. To date, the
venture has been described in little detail in the literature.
The 100,000 Genomes Project
The venture’s launch
Decades of promissory discourses surrounding genetics and genomics have situ-
ated this ﬁeld at the heart of many political health/research discussions in the
UK, as well as internationally. Added to this, ex-UK Prime Minister David Camer-
on’s personal journey of having lost a son due to a genetic condition meant that the
political climate in the UK was perhaps more open and willing to fund such pro-
missory discourses into action. Thus, in 2009, and as part of the long political
drive to implement genomics into healthcare, the UK House of Lords Science
and Technology Committee called for the development of a “strategic vision for
genomic medicine in the UK.”2 In response, the Government established the
Human Genomics Strategy Group designed to monitor advances in genomics
and develop a vision for the discipline within the NHS. The Strategy’s 2012
report explained the various steps needed to streamline genomics within the
NHS and as such laid the foundations of the 100,000 Genomes Project (Human
Genomics Strategy Group 2012, 9). Soon after the publication of this report, the
venture was launched with the advertised aim to sequence 100,000 genomes of
NHS patients, focusing on rare disease, cancer, and infectious disease. Its central
goal is to implement genomics innovation on a national scale such that it
becomes routine in NHS practice, though it also has an additional research goal
(i.e. it is an innovative clinical–research hybrid project). The project received
over £200 million in initial investment (Monitor Deloitte 2015).
More than just whole genome sequencing
While the Genomes Project bore out of a desire to bring patient beneﬁt, to improve
NHS infrastructure, and to drive research in the genetics arena, it also has the aim of
kick-starting the development of a UK genomics industry.3 Thus, as with many bio-
technologies, the project was “justiﬁed in terms of [its] potential to generate econ-
omic value” and exempliﬁes the “bioeconomy” at play (Petersen and Krisjansen
2015, 30). Indeed, the venture can be directly viewed as the realization of the Gov-
ernment’s 2003 vision to lead the world in harnessing the potential of genetics in
healthcare (Department of Health 2003), and as such is expected to create oppor-
tunities for the genomics industry (Monitor Deloitte 2015). These opportunities
are anticipated to come from services related to the Genomes Project such as the
sequencing of the DNA, the data analysis, and the clinical interpretation. It is
also foreseen that as the scale of genomes data grows, analysis and interpretation
services will be in high demand, driving investment in areas such as analytics,
data management, and data storage. As the Ofﬁce for Life Science’s Genomics
New Genetics and Society 3
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in Industry report has noted, the UK currently contributes 10% to the £8 billion
global genomics market and it is anticipated that the genomes venture will
double this proportion. The project is therefore much more than a DNA sequencing
project. Moreover, it is about implementing the sequencing and interpretation of
genomics into the NHS not only to bring patient beneﬁt, but also for this beneﬁt
to be realized in terms of economic and industrial “bio-value” (Rose 2001;
Waldby 2002; Petersen and Krisjansen 2015).
The National Health Service
Genomics England is the limited company wholly owned by the Department of
Health tasked with carrying out the rare disease and cancer arm of the Genomes
Project, though it is the UK’s NHS which has been tasked with delivering the
venture. As such, the NHS has been deemed responsible for recruiting and consent-
ing patients to the project, capturing clinical information about patients to inform
DNA sequence analysis, and collecting and handling patients’ DNA samples
prior to analysis. The latter function includes the processing of DNA samples:
DNA extraction; barcoding, handling, identiﬁcation; transport and transfer of
samples; and sample storage. In order to fulﬁll its mission, in 2014 NHS
England announced the formation of 13 Genomics Medicine Centres (GMCs)
throughout the UK. These centers, each constituted of a number of alliance hospi-
tals and organizations, were selected because of their track-record of providing
excellence in genomic services. Their aim is to bring transformational change to
the infrastructure of genomic medicine care delivery by delivering an end-to-end
genomic medicine pathway. In spite of this, at the time of writing this paper (begin-
ning of 2017), Genomics England/NHS were behind in their recruitment, with just
over 17,000 genomes having been sequenced and far, far fewer sequences being
analyzed or results returned. Our ﬁndings in this paper provided some insight
into the reasons behind this.
Commercial and academic partners
While the NHS is tasked with the delivery of the genomic vision, Genomics
England is responsible for procuring the sequencing capacity, the data architecture,
and the necessary tools to securely store and interpret the 100,000 sequences and
allow access for clinicians and researchers.4 To do this, Genomics England has
formed a number of partnerships with a range of commercial and academic part-
ners. For example, to sequence the DNA, Genomics England formed a partnership
with the Wellcome Trust, The Wellcome Trust Sanger Institute and Illumina to
create a Genomic Medicine Sequencing Centre in Hinxton,5 near Cambridge,
UK. In terms of data analysis and interpretation, Genomics England has established
the Genomics England Clinical Interpretation Partnership (GeCIP) of more than
2000 funders, researchers, trainees and clinicians from across the UK and the
4 G.N. Samuel and B. Farsides
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world. One of the main purposes of this partnership is, via carefully controlled
access to the data, to allow those within the partnership to conduct beneﬁcial
and useful clinical research on the genomic data. This partnership also has the
broader role in health professional education and training. As yet, the partnership
is not up and running to its full potential, and it is still too early to tell whether
this framework for analysis will be successful in the future. Genomics England
has also established the Genomics Expert Network for Enterprises (GENE) Consor-
tium – a selection of industry partners who are allowed access to Genomics Eng-
land’s data during an industry trial throughout 2015. In this consortium, Genomics
England remains the owner of the genomic sequences (along with the consequent
legal and ethical consequences of this) and members are expected to pool knowl-
edge and share the results of their analysis.6 However, again, little is known about
the outcome of this trial or whether this approach to interaction with industry has
been productive. Moreover, little is yet known about how the ethical issues associ-
ated with partnering with commercial entities might unfold. Though Genomics
England does have an independent Ethics Advisory Committee to aid with
ethical decision-making in relation to Genomics England’s policies and practice.
Methods
Rationale
As a medical ethicist and a medical sociologist working in the ﬁeld of ethics, we
were particularly interested in exploring how ethical issues associated with the
Genomes Project have been, and are being, addressed by individuals on its
Ethics Advisory Committee, as well as by those involved in the policymaking
aspect of the initiative more broadly. We conducted 20 interviews with members
of the Ethics Advisory Committee, the board of Genomics England, staff
members, and those more broadly associated with the project to explore these
issues. Some interesting insights emerged from our data with relation to how
“ethics” was framed and performed within the organization. However, increasingly,
during the course of our interviews, it was striking how much of the participants’
narratives revolved around the policymakers’ expectations of the project. It is these
ﬁndings which are reported here. This is in line with the similar experiences of
Bobbie Farsides, in which during a project exploring “new genetics” in ante-
natal care, health care professionals were more interested in talking about issues
relating to Down’s Syndrome.
Recruitment
Potential respondents were recruited in the summer of 2016, at the approximate
half-way mark through the 100,000 Genomes Project. Invites requesting partici-
pation in the research study, including participant information sheets, were
emailed to individuals associated with, or those who worked for, Genomics
New Genetics and Society 5
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England. Individuals from the following categories were invited: Genomics
England staff members; Genomics England board members; Ethics Advisory Com-
mittee members; representatives from the Department of Health, Public Health
England, NHS England, GMCs; and those involved in the evaluation of the
100,000 Genomes Project. Board member Professor Mike Parker and Head of
Ethics, Laura Riley, assisted with recruitment by providing the names and email
addresses of relevant individuals. Individuals were requested to respond to the
email invite if they were interested in participating in the research project, or if
they had any questions. A maximum of two follow-up emails were sent to non-
responding individuals.
Interviews
Twenty individuals responded to the email invite and 20 semi-structured interviews
were conducted. All of the categories of individuals listed in the above section were
represented in the interviews (exact n numbers are not provided to protect conﬁden-
tiality given the small-scale nature of the project). All participants signed a consent
form prior to the interviews commencing. Interviews were conducted either by tel-
ephone or face-to-face (at a location chosen by the participant), lasted between 30
and 105 minutes, and were audio-recorded. The interview schedule was broad,
asking participants about their background and their role associated with the
100,000 Genomes Project. Participants were also asked their views on the
project; on its beneﬁts (present and potential) and drawbacks; on any issues they
had come across in relation to their role in the project and how these had been over-
come; and on the project’s political basis, as well as its ethics and public engage-
ment strategy. Interviews were transcribed either by Gabrielle Natalie Samuel or by
an external transcribing service.
Analysis
Analysis of interview data was approached using inductive reasoning employing
the inductive approach of grounded theory (Strauss 1987; Charmaz 2006). The
analysis (or coding) of data was based on two inter-linked rounds: overview analy-
sis and detailed analysis (Strauss 1987). Overview analysis consisted of memo-
making and broad coding. Extensive memo-making was employed by the inter-
viewer directly after each interview. Broad coding proceeded by scanning the inter-
view transcripts for relevant ideas and themes. Detailed analysis of the full
transcripts occurred line-by-line using NVivo software. Coding was carried out
via constant comparison, which was continual, rigorous and allowed for develop-
ing and reﬁning of conceptual categories as theory was developed. Due to the
limited number of individuals associated with Genomics England, and the need
to protect conﬁdentiality, comparisons between respondents from different insti-
tutions are not reported.
6 G.N. Samuel and B. Farsides
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Ethics approval
Ethics approval was granted by Brighton and Sussex Medical School Research
Governance and Ethics Committee (RGEC). Reference 16/014/FAR.
Findings
Interviewee’s narrated two accounts of policymakers’ expectations about the
100,000 Genomes Project. One account pointed to a wide-range of issues which
were hindering the project’s implementation into clinical practice as an illustration
of why policymakers’ aspirations to sequence 100,000 genomes by 2017 were
overly optimistic. Their dialogues resonated with previous literature which we dis-
cussed earlier, that highlights the pitfalls of unfulﬁlled promissory “genohype”
often associated with genetic/genomic innovation (Brown and Michael 2003;
Borup et al. 2006; Petersen and Krisjansen 2015). In the other contrasting
account, interviewees’ perceived the expectations attached to the 100,000
Genomes Project as mobilizing an impetus in their attempts to overcome a wide-
range of issues which were hindering the project’s clinical implementation.
Below we explore these two accounts in detail. We note that the accounts of
each interviewee could be situated within either narrative, somewhere in
between, or as a mixture of both. We are careful not to identify participants in
terms of their organizations, but note that there was some, though little, in the
way of distinction between where interviewee’s accounts sat within or between
these two different narratives and their respective host Institutions or job roles.
Over optimistic expectations and genohype
In our interviewees’ ﬁrst account of the promises associated with the 100,000
Genomes Project, the expectations of policymakers were viewed as “optimistic”
(interviewee 4) and “overpromised” (interviewee 20). Interviewees pointed
toward the as yet under performance of Genomics England in achieving its goals
(roughly 17% of genomes sequenced at time of interview, midway between the
project). These feelings of over overpromise rested almost in their entirety on the
short time scale with which the project needed to be completed. There was an
awareness that while the relative ease with which genomes can be sequenced
marked one of several spurs for the development of the project, sequencing
100,000 genomes was much more complicated than the mere act of DNA sequen-
cing. Sitting on one side of this was a complexity to “making sense of it [the
sequence]”: “you can churn out 3 billion base pairs for $500 probably, but how
much does it cost to make sense of it” (interviewee 3). This was especially true
given the dual research–clinical nature of this project and the fact that innovation
was occurring alongside delivery – the technology to handle and interpret such a
large genomic data set was being developed concomitant to the collection of
samples. On the other side, and the side focused on within this paper, there was
New Genetics and Society 7
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the necessity to recruit patients and collect samples. Here, interviewees explained
that the expectations attached to the project were unrealistic because the delivery
and implementation of the project was to be carried out by the NHS. As such,
much of the success of the 100,000 Genomes Project was “dependent on hospitals”
(interviewee 15), relying on them to recruit individuals and collect DNA samples. It
was acknowledged that the promise of the genomes venture was entering an already
socially organized environment (the NHS) with its own ﬁrmly embedded political
interests, as well as organizational, social, professional and cultural norms (“there
are lot of social and institutional and professional and cultural barriers in the way of
it working” (interviewee 13)). Such norms involved differing expectations about
genomics, the importance of the Genomes Project, and its associated aims. A realiz-
ation existed that to achieve the transformational shifts within the time frames of the
project, a change in the thinking of the NHS and its staff towards genomics, and
speciﬁcally this project, was needed. Altering these norms and expectations to
harbor the project was seen as one of the keys to the project’s success. This,
however, was perceived as not easy, with interviewee 4 noting that “there is the
problem about how you persuade clinicians to join in . . . [because] . . . it is very dif-
ﬁcult to shift NHS clinicians to that [genomic England’s] position” (interviewee 4).
Indeed, speaking about organizational shifts post sequencing, interviewee 10, for
example, noted that unanswered questions remained about how such a “transforma-
tional” (interviewee 9) change of the NHS could occur:
Right from the start was . . . the knowledge that GEL [Genomics England Ltd] gen-
erated would inform clinical practice in the NHS, and that brings with it a number
of organizational tensions . . . is the infrastructure of the NHS going to be capable
of incorporating this knowledge? Will we have the ability to use it properly? . . .
What’s the skill needs that we will need within the health service to be able to
deliver genomic medicine quickly and equitably? So there are a huge number of
issues that need to be resolved or need to be addressed for it to be successful
Such tensions were viewed as especially pertinent by many interviewees given the
“cash-strapped busy NHS” (interviewee 11): “when you actually put yourself down
in the trust with its own costs and constraints, and many of the trusts are under
special ﬁnancial measures, that’s not their key priority” (interviewee 12).
Interviewees’ accounts revolving around overpromise were therefore contextua-
lized by the friction emerging between on the one hand those working at Genomics
England needing to meet the grandiose expectations of the 100,000 Genomes
Project set by policymakers, and on the other, the differing priorities, expectations,
cultures, norms, and organizational landscape of the NHS as a ground for clinical
implementation of the project: “I don’t think we knew when we started . . . how
complex it would be to build the infrastructure . . . you could say we may have
been naı¨ve” (interviewee 4). Interviewees provided detailed examples to substanti-
ate their views about policymakers’ unrealistic expectations and below we brieﬂy
note two such illustrative examples.
8 G.N. Samuel and B. Farsides
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Examples of the types of issues faced during clinical implementation
The 100,000 Genomes Project requires that about 70,000 patients (100,000
sequences) be recruited to the project via the NHS. However, as all interviewees
noted, this has not been an easy task for the cancer arm of the study (“cancer
has been difﬁcult..[..]..in cancer they are struggling” (interviewee 10)) due to the
differing priorities, expectations and culture of the NHS. For example, for intervie-
wee 11, the research–clinical hybrid nature of the project meant that, rather than
falling on an employed research nurse, recruitment responsibilities fell onto front-
line clinical healthcare professionals – a staff team which was already “stressed”
and “busy,” and maybe not very interested in assisting the genomes venture
achieve its goals and fulﬁll its expectations:
if you go along and saywell this patient’s in a research study and that they need an extra
two blood samples taken in half an hour, can you do that..[..].. if you’re in a stressed
busy clinical environment; it’s easier to not ask the question . . . (interviewee 11).
Compounding this was the fact that many on this staff team may have little interest
in research, or pursuing research endeavors:
I don’t think it’s [research] is as embedded in the frontline NHS psyche as we like to
think it is . . . .some nurses think that research is just and add on and a faff and they
don’t want to worry about it. So I think there’s a culture change to be done . . . [..]..it’s
back to anything that makes things a bit different for them. They’ve got their routine,
just processes that they do (interviewee 11)
For interviewee 18, a different concern about the differing priorities of the NHS
versus the Genomes Project was apparent. This interviewee viewed a potential
gap between executive support for the venture, and those individuals who are actu-
ally responsible for NHS day-to-day frontline recruitment. And, as this interviewee
explained, for the latter, many clinical healthcare professionals may have personal
and ﬁnancial interests elsewhere, within their own already secured separate
research funding. As such, recruitment for the project might be de-prioritized:
clinicians that work for the local trust and whose own research grants come from
[other research funding bodies] are simply saying “right, I’ve got this person to
agree to a clinical trial; let’s not complicate the issue by throwing anything else in”
(interviewee 18).
This was also of institutional concern, where the already high prevalence of clinical
trials occurring within clinical cancer centers meant that vested interests remained
here as opposed to the new genomics project in terms of removing samples from
patients:
A lot of the cancer trials currently going on require samples and there’s an issue about
how big the samples need to be to satisfy both Genomics England’s requirement and
Cancer Research UK’s requirements. So I think there’s an argument there about just
how much ﬂesh you can cut out of one human being; [and also] the clinical trial
New Genetics and Society 9
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requires tissue samples to be taken in this way and to be preserved in that way, that
does not ﬁt Genomics England’s needs, ﬁne, they’re not going to look into it (inter-
viewee 18)
Beyond these issues with recruitment, for the Genomes Project to be successful
once recruitment had occurred, DNA samples need to be collected from partici-
pants for sequencing. However, similar to previous issues noted in the literature
(Lazaridis et al. 2014), technical issues have emerged with the collection of
cancer samples for genomic sequencing because the way in which tumor
samples are routinely stored for processing damages DNA. Interviewee 16
explained that changing the sample processing protocol meant a huge organiz-
ational, professional, as well as cultural shift within the NHS: “what we had to
do is to reengineer the way the National Health Service does this across its 13
Genomic Medicine Centres . . . ” and as interviewee 7 noted, this meant “develop-
ing new approaches to the handling of tissue, and as soon as you’re saying you’re
going to do that, your reforming processes deep at the heart of pathology across the
NHS” (interviewee 7). Interviewee 17 advised that while such changes may not
seem like “rocket science,” they are often the hardest to implement in practice
because of differences in priorities and expectations within an already stretched
NHS.
It’s not rocket science. It involves . . . steps like having someone on hand to carry the
sample from the theatre to the path lab. Now, an actually busy hospital, just organiz-
ing that is not immediately obvious . . . it then can’t take two or three days to get to the
path lab. It has to actually go there in a few hours . . . so all of that is in an NHS which
is under pressure for all sorts of reasons, is not an easy thing to do . . .
This change was perceived as particularly difﬁcult and interviewee 4 was becoming
increasingly frustrated that the NHS laboratories, who maybe did not share the
vision of policymakers’ expectations about the Genomes Project, were opposing
change to their “outdated model” of pathology testing:
I think that someone needs to take people that run genomics labs in the NHS by the
scruff of their necks and shake them up to the fact that . . . . power comes from having
high quality data that you use and that they are trying to keep to an outmoded model.
Overall then, the instances described above, and similar issues (including, but not
limited the lack of resources and staff within the NHS to accommodate the trans-
formation change, and the lack of education and support and to want to drive the
change), were used by interviewees as illustrative exempliﬁers of the overly opti-
mistic expectations associated with the Genomes Project that it could fulﬁll its
promises, and of the “underestimated” time (interviewee 9) provided with which
to achieve said aims. Most of these instances can be tied together by the realization
of a tension between the need for Genomics England to implement its aims, and the
fact that the NHS as an organizational structure did not, and more importantly could
not, always share the same vision of genomics. Indeed, the “cash-strapped” NHS
10 G.N. Samuel and B. Farsides
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Su
sse
x L
ibr
ary
] a
t 0
7:0
9 2
9 S
ep
tem
be
r 2
01
7 
had/has its own set of issues to face on a day-to-day basis far removed from the
implementation of genomics. And interviewee 5 noted that whilst the project
was not “misconceived, [it was] rather simplistically assumed how easy it would
be.” Interviewee 12 stated that “a very bold statement [the 100,000 Genomes
Project announcement], but in terms of delivery, it just makes it impossible to do.”
Expectations and the mobilization of motivation
Interviewees also had an alternative account to the above perspective on policy-
makers’ expectations of the Genomes Project. From this second perspective, inter-
viewees viewed the hype surrounding the venture as a mobiliser of the project. In
this narrative, the project’s political foundations were seen to bring beneﬁts: “the
most difﬁcult thing is that we are a political project, but that’s also the biggest
advantage” (interviewee 2). This was because the time pressure, borne out of the
need to meet the expectations attached to the project meant that “[the project]
wouldn’t have happened probably as quickly without that policy support” (intervie-
wee 11); “we are where we are and a lot quicker than we would have been” (inter-
viewee 17). And while the fast-pace of the project meant that it was “all a bit of a
learning process” (interviewee 9), with very little time to plan ahead (“we are build-
ing the airplane while we are ﬂying it” (interviewee 15)) so that some mistakes were
being made (“you make mistakes” (interviewee 17)), at the same time, it had its
beneﬁts. The speed was seen as “one of the ways to innovate really rapidly” (inter-
viewee 16), and allowed years of “painful” planning to be avoided: “you ended up
in these scenarios where people were trying to plan for every possible circumstance
and it was incredibly painful and it was still chaotic at the end” (interviewee 2). As
such, the political nature of the project, although causing friction, provided a “can-
do attitude” (interviewee 1), and was “needed” to force paced decision-making: “I
think the friction that has happened, the pace of things, I think that needed to
happen because academics would always – they would take far too long to
come to this decision” (interviewee 18). Interviewee 2, for example, spoke about
the political rhetoric giving the project “impetus” to drive change:
the fact that we are a political project with a political view means that we have that
focus to be concentrated on driving a lot of the change . . . there is a lot of political
rhetoric around it because that’s what’s given it the impetus (interviewee 2).
In this account of policymakers’ promises, interviewees perceived the project’s
tightly framed expectations and deadlines as working positively to help surmount
the issues facing the project’s clinical implementation described above. This was
because the speed with which the Genomes Project needed to work to meet such
expectations was viewed as the necessary factor to drive change in NHS culture:
“if you go to slowly you end up with compromise of the lowest common denomi-
nator. The objective was absolutely to drive this fast, to have the NHS and our
researchers ahead . . . and not to give people time to downgrade it” (interviewee
4). As interviewee 17 remarked, the idea was that if the project – which needs
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to overhaul NHS services – moves fast enough, the NHS would not have time to
“work out its defence” to any organizational, cultural, social, and professional
changes required within the NHS, thus making any transformations easier:
If you’re not careful, you get caught up in normal human defence to change. If you
move fast enough, you can, to a degree, minimize that [laugh] . . . I’m told by people
who’ve been in the business much longer than I have that all previous attempts to
reform pathology have failed. But we seem to be getting there. I think that’s possibly
because we’ve arrived at such speed . . . we had to change before the system worked
out its defence to that (interviewee 17)
Therefore, while the project did raise a range of clinical implementation issues, the
alternative, that is, not implementing the project with the policymakers expec-
tations attached, was not viewed as necessarily any better:
change is always painful [and] . . . I recognize the challenges [of having the political
expectations tied into the project], but when people talk about alternatives, I think that
they are perhaps being a little naı¨ve in thinking that those alternatives would necess-
arily be better (interviewee 2).
In fact, while the nature of the expectations meant that it was “uncomfortable” and
“tough” for the workforce who were trying to implement the Genomes Project, it
was the tight deadlined expectations themselves which, in essence, provided the
motivation and momentum that was needed as they attempted to drive a cultural
shift in priorities within the NHS:
I think it’s very uncomfortable for everybody . . . but I think it’s a very brave project
and it is one way to get the NHS to change systems is just to say it’s changing and see
how everybody innovates and how everybody works around that and I think that is
the policy, that is the motivation. So I probably think it’s a good thing, a good thing
for patients eventually . . . (interviewee 9)
This is not to say whether or not this expectation-driven motivation would lead to
the project’s success, since we have no way of knowing this from this data, but
rather there was a view that the policymakers’ expectations mobilized an
“impetus” and motivation for individuals within Genomics England in their
attempts to drive the project forward.
It is worth noting that having one entrepreneurial company – Genomics England,
both responsible and answerable for meeting the expectations for the project’s
eventual success, most likely facilitated the momentum/motivational affects of
the policymakers’ expectations. Having this focal point meant that the impetus
and drive could abound throughout the company, its staff and associated individ-
uals. These could then be championed outside the project more broadly (Lazaridis
et al. 2014; Kukk, Moors, and Hekkert 2016). Indeed, interviewee 3 felt that the
status of Genomics England as an entrepreneurial company meant that in the
face of tight deadlines and expectations, it was more likely than academics/scien-
tists to adopt a can-do attitude in the face of trying to change NHS clinical culture:
12 G.N. Samuel and B. Farsides
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it’s very difﬁcult to get the [translational] stuff into the clinic, and I think part of the
problem is science itself and scientists. They are not brave enough..[..]..the entrepre-
neur [Genomics England] . . . will take a judgment . . . and then will do something
about it.
Concluding remarks
This paper has explored how policymakers’ expectations manifested within the
UK’s recent and ongoing 100,000 Genomes Project. Our interviewees’ narrated
two accounts relating to this. The ﬁrst emphasized the various understandable
issues hindering the project’s implementation into clinical practice as an illus-
tration of what interviewees viewed as the overly optimistic “genohype” associ-
ated with the project. In constructing this narrative, interviewees’ accounts
reﬂected what is already known about the complex process of implementation
(May and Finch 2009) and thus viewed the grandiose statements and promises
afﬁxed to the Genomes venture as “naı¨ve” and “overpromised.” The second
account perceived the expectations of the project, particularly given the time con-
straints attached to them, as acting as an impetus and motivator of Genomics
England’s efforts to drive clinical implementation and delivery. This can be com-
pared to previous work exploring the future-orientated expectations attached to
other biomedical innovations/other genetic/genomic technologies, which have
been shown to do performative work in the generation of funding, the promotion
of alliance building and the allocation of resources (Hedgecoe and Martin 2003).
Only here, in a company which has been already fully funded, the expectations
are functioning as a stimulus for individuals within Genomics England, working
to drive change.
The presence of these two different accounts of the 100,000 Genomes Projects’
political expectations immediately suggests a possible relevance of the work of
Gilbert and Mulkay. These authors have drawn on extensive research in the ﬁeld
of biochemistry, and in particular oxidative phosphorylation, to argue that scien-
tists’ descriptions of their actions and beliefs about science are context-speciﬁc.
The authors note two predominant styles of interpretation of events: those in the
formal context, based on an empiricist repertoire (i.e. often seen in academic jour-
nals – science as impartial; scientists are detached) and those in the informal
context, based on a contingent repertoire (i.e. drawing on social, psychological
and other factors), often used to explain away controversies or “others’” errors in
science. Such discourses, say the authors, are reconciled by the belief that social
distorting inﬂuences which cause errors and controversies in science will even-
tually be made apparent and science will prevail (Gilbert and Mulkay 1984). The
authors argue that both discourses are equally important and valid, and rather
than trying to combine them to form one interpretation of events (as is typically
the case), they recommend different participants’ discourses be treated as a topic
of analysis as a whole made up of different but not necessarily inconsistent parts.
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Applied to our ﬁndings, this would suggest that interviewees’ discussions pro-
moting the beneﬁts of the political expectations attached to the Genomes Project
reﬂect the formal, empiricist repertoire or version of events, whereas interviewees’
discussions about the difﬁculties faced by the project are contingent – interviewees
maintain their own credibility and that of Genomics England by explaining away
difﬁculties using “genohype” and other social/organizational issues such as those
related to the need to rely on the NHS. This is an interesting way to consider our
ﬁndings, and sits alongside the approach we have taken.
Moving beyond a discourse approach, some of our ﬁndings are not unexpected.
Interviewees accounts of overpromise and issues with clinical implementation are
unsurprising given that those who are involved in the project are likely to want to
explain how hard the project has been, and express concern about being able to
deliver the project – especially given the issue of resources within the NHS, a
point further explored by Day and colleagues in their ethnographic study of a
large, research intensive NHS breast cancer service implementing a stratiﬁed medi-
cine approach (Day et al. 2016). More surprising were interviewees’ perspectives
on the beneﬁts of working under difﬁcult time constraints – constraints which were
also viewed as overpromised. One might expect that interviewees would only have
negative things to say about working under these conditions (and a lot of them did
indeed express the pressure which had been placed on the workforce). Yet this was
not always the case, beneﬁts were also noted. Talking to individuals at Genomics
England suggested that when trying to make a big (national) shift from research to
the clinic, working to tight deadlines, and working within a pressured environment,
while “tough” and “uncomfortable”, was having a motivational role. This was seen
as then acting to provide the momentum required by Genomics England in its
attempts to drive change in clinical practice – a practice which is well known to
be particularly resistant to such change and a phenomenon sometimes referred to
as clinical inertia. This is not to say that the impetus and motivation generated
from policymakers’ expectations will indeed bring about the project’s success –
we have no way of knowing if the project will be successful from this data, and
indeed (while not genome sequencing), Day and colleague’s ethnographic study
suggests a whole range of issues affecting patient care during the implementation
of a stratiﬁed medicine approach (Day et al. 2016). Rather, with well-acknowl-
edged time constraints hanging over Genomics England, the expectations attached
to the Genomes Project inadvertently acted as a currency of hype (Petersen and
Krisjansen 2015) – a vision of what needed to be achieved. This then provided
a stimulus, a perceived necessary factor, as Genomics England attempted to
drive clinical change. This can be compared to other “currencies of hype” and pro-
missory discourses disseminated by companies within the ﬁeld of genomics, for
example those associated with the synthetic biology “Biobricks group,” explored
by Hilgartner (Hilgartner 2015), and those associated with deCODE Genetics –
explored by Fortun (Fortun 2001). In the latter case, Fortun argued that the prom-
ises, hype, and “stories” promoted by deCODE genomics were integral to the
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science and business of the company, and that “to the extent that we can say it is
‘based’ on anything, the genomics industry is based on . . . what genetic infor-
mation may become in the anticipated, contingent future . . . . there can be no
economy without hype . . . ” (Fortun 2001, 145–146). While our ﬁndings
suggest a positive role for the presence of such hype and promissory discourses,
Fortun in comparison, comments that
six years of researching, speaking on, and writing about deCODE . . . here is a case so
chock-full of false and broken promises . . . that I can conﬁdently make the “forward-
looking statement” that Kari Stefansson [CEO and founder of deCODE] has the least
right to make promises of any genomics company CEO I know (Fortun 2005, 158).
Happily, the researchers in this instance were not compelled to reach a similar
conclusion.
To summarize, then, these ﬁndings caution us not to view the genohype surround-
ing the venture as just vacuous hype, something which is hindering the project, or is
problematic because it over promises what cannot be delivered. While the project
may have been “overpromised” and “misconceived” (it is too early to tell), the pro-
missory discourses attached to it have become a part and a drive of the project itself.
Having an entrepreneurial Genomics England with full responsibility for achieving
the project’s promised political goals as a focus for this drive and motivation, and
having a speciﬁc time frame with which Genomics England needs to meet these
expectations, has allowed the project to acquire momentum as Genomics
England uses all its effort to enact change at the level of clinical delivery. Thus,
while expectations and promissory discourses can lead to negative outcomes (as
noted in relation to Fortun’s analysis of deCODE above (Fortun 2005)), it is impor-
tant to recognize that this is not always the case. These ﬁndings should be con-
sidered during the development of any future genomes projects within the UK,
and also internationally.
By way of limitations, we note that our interviewees were self-selecting individ-
uals approached through a contact list provided by Genomics England. This self-
selection of participants may have created a particular bias, and there may have
been others at the company who would have provided valuable insight about
the company who did not participate in the study. Furthermore, the interviews
were conducted in 2016, before the 100,000 Genomes Project’s completion. As
we have noted above, further research needs to be conducted to explore how the
innovation process progresses; whether (and/or how) successful clinical delivery
is implemented; and whether the promissory discourses associated with the initiat-
ive lead to real beneﬁts, or whether these “communities of promise” – or “geno-
hype” – fall apart and migrate to new areas, as described in the “sociology of
expectations” (Michael 2000; Brown and Michael 2003; Borup et al. 2006).
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Notes
1. Other research–clinical hybrid projects not on a national scale include, for example, the United
States Geisinger health systems’ MyCodew genomics data system and biobank, and the United
States Mayo Clinic’s Center for Individualized Medicine. The research–clinical hybrid setup is
interesting in terms of novel conceptions of innovation pathways and is the subject of a
forthcoming paper (Dheensa et al.).
2. http://www.publications.parliament.uk/pa/ld200809/ldselect/ldsctech/107/10711.htm.
3. https://www.genomicsengland.co.uk/about-genomics-england/.
4. https://quarterly.blog.gov.uk/2014/01/30/100000-genomes/.
5. https://www.genomicsengland.co.uk/wp-content/uploads/2014/11/GeCIP-Guidance_FINAL.
pdf.
6. https://www.genomicsengland.co.uk/clinicians-researchers-and-industry-collaborate-with-the-
100000-genomes-project/.
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